SGLT2 inhibitor early after heart attack to protect the heart
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether giving an SGLT2 inhibitor (a diabetes medicine that may also protect the heart) early after a heart attack can help shield the heart from damage. It is for people having a first-time STEMI heart attack who have adequate kidney function and stable blood pressure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are having a specific type of heart attack (STEMI) that shows up on an EKG.
- You are between 18 and 80 years old.
- Your kidney function is good enough (eGFR above 45).
- Your blood pressure is above 110/70 mmHg before taking the study drug.
- You have not had a heart attack before, and you do not have certain other health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.
This study looks at how starting an SGLT2 inhibitor (a diabetes medicine) around the time of a heart attack affects heart outcomes and heart muscle changes over time. It may help you and your care team understand whether this timing is beneficial after a PCI procedure.
This trial tests whether a diabetes drug called dapagliflozin can help people recover from a major heart attack (STEMI). You may qualify if you had a large heart attack within the last 12 hours and have not had a heart attack before.
This Phase 2 trial tests whether an SGLT2 medicine started after a first STEMI heart attack can reduce ongoing heart muscle injury and scarring. It may help people who, based on heart imaging, have larger infarcts and ongoing microvascular damage.
This study tests whether a diabetes medication called ertugliflozin can help protect your heart function after a heart attack. Researchers want to see if starting this medicine early (within 3 days) helps your heart recover better.
This trial tests whether dapagliflozin (a diabetes medicine also used for heart protection) can reduce harmful heart “remodeling” after an acute heart attack. It may help your heart function and structure recover over the following 6 months.
Hear when a new Myocardial Infarction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.